Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnose... by Theo Leitner, Evgenii Shumilov, Christina Schwitlick, Raphael Koch, Franziska Hamm, Marion Högner, Florian Bassermann, Katja Weisel, Hermann Einsele, Martin Kortüm, Leo Rasche, Martin Görner, Kai Wegehenkel, Stefan Knop, Jan Krönke, Axel Nogai, Inke R. König, Maren Vens, Kay Horn, Nikolas von Bubnoff, Cyrus Khandanpour

Get full text

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐u... by Elias K. Mai, Axel Nogai, Henk M. Lokhorst, Bronno van derHolt, Sonja Zweegman, Katja C. Weisel, Sandra Croockewit, Anna Jauch, Jens Hillengass, Marian Stevens‐Kroef, Marc S. Raab, Annemiek Broijl, Gerard M. J. Bos, Peter Brossart, Paula Ypma, Christine Hanoun, Uta Bertsch, Thomas Hielscher, Hans J. Salwender, Christoph Scheid, Hartmut Goldschmidt, Pieter Sonneveld

Get full text